13. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padro T (2006) Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 6: 439– 456. 14. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L (2000) LDL receptor- related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 1572–1579. 15. Llorente-Cortes V, Otero-Vinas M, Sanchez S, Rodriguez C, Badimon L (2002) Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 106: 3104–3110. 16. Llorente-Corte´s V, Otero-Vin˜ as M, Hurt-Camejo E, Mart´ınez-Gonza´lez J, Badimon L (2002) Human Coronary Smooth Muscle Cells Internalize Versican- Modified LDL Through LDL Receptor–Related Protein and LDL Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 387–393. 17. Llorente-Cortes V, Otero-Vinas M, Berrozpe M, Badimon L (2004) Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur J Clin Invest 34: 182–190. 18. Padro T, Pena E, Garcia-Arguinzonis M, Llorente-Cortes V, Badimon L (2008) Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 77: 211–220. 19. Garcia-Arguinzonis M, Padro T, Lugano R, Llorente-Cortes V, Badimon L (2010) Low-density lipoproteins induce heat shock protein 27 dephosphoryla- tion, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 30: 1212–1219. 20. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101: 207–213. 21. Brookes ZL, McGown CC, Reilly CS (2009) Statins for all: the new premed? Br J Anaesth 103: 99–107. 22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301– 1307. 23. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, et al. (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338: b2376. 24. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267– 1278. 25. Scandinavian Simvastatin Survival Study G (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 344: 1383–1389. 26. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C- reactive protein. N Engl J Med 359: 2195–2207. 27. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556–1565. 28. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, et al. (2001) Effects of lipid- lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104: 249– 252. 29. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, et al. (2005) Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 46: 2022–2030. 30. Yamagami H, Sakaguchi M, Furukado S, Hoshi T, Abe Y, et al. (2008) Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol 34: 1353–1359. 31. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, et al. (2008) Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155: 584 e581–588. 32. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, et al. (2010) Aggressive lipid-lowering is more effective than moderate lipid- lowering treatment in carotid plaque stabilization. J Vasc Surg 51: 114–121. 33. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, et al. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926–933. 34. Schafer K, Kaiser K, Konstantinides S (2005) Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 93: 145–152. 35. Gronros J, Wikstrom J, Brandt-Eliasson U, Forsberg GB, Behrendt M, et al. (2008) Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis. Am J Physiol Heart Circ Physiol 295: H2046–2053. Rosuvastatin and Migration of LDL-Loaded VSMC 36. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, et al. (2003) Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 10: 109–116. 37. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L (1998) Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol 18: 738–746. 38. Guyton JR, Klemp KF, Mims MP (1991) Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J Lipid Res 32: 953–962. 39. Pentikainen MO, Lehtonen EM, Kovanen PT (1996) Aggregation and fusion of modified low density lipoprotein. J Lipid Res 37: 2638–2649. 40. Llorente-Cortes V, Otero-Vinas M, Badimon L (2002) Differential role of heparan sulfate proteoglycans on aggregated LDL uptake in human vascular smooth muscle cells and mouse embryonic fibroblasts. Arterioscler Thromb Vasc Biol 22: 1905–1911. 41. Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L (2003) Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ Res 92: 96–103. 42. Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P (1999) Inhibition of myosin light chain kinase by p21-activated kinase. Science 283: 2083–2085. 43. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, et al. (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho- kinase). J Biol Chem 271: 20246–20249. 44. Llorente-Cortes V, Casani L, Cal R, Llenas A, Juan-Babot O, et al. (2011) Cholesterol-lowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia. Eur J Clin Invest 41: 1087–1097. 45. Sendra J, Llorente-Cortes V, Costales P, Huesca-Gomez C, Badimon L (2008) Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 78: 581–589. 46. Lupu F, Heim D, Bachmann F, Kruithof EK (1994) Expression of LDL receptor-related protein/alpha 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb 14: 1438–1444. 47. Crouse JR, 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, et al. (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low- risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297: 1344–1353. 48. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 629–635. 49. Pertz O (2010) Spatio-temporal Rho GTPase signaling–where are we now? J Cell Sci 123: 1841–1850. 50. Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116: 167–179. 51. Wu C, Horowitz A (2011) Membrane traffic as a coordinator of cell migration and junction remodeling. Commun Integr Biol 4: 703–705. 52. Heasman SJ, Ridley AJ (2010) Multiple roles for RhoA during T cell transendothelial migration. Small Gtpases 1: 174–179. 53. Seasholtz TM, Brown JH (2004) RHO SIGNALING in vascular diseases. Mol Interv 4: 348–357. 54. Camino-Lopez S, Llorente-Cortes V, Sendra J, Badimon L (2007) Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 73: 208–216. 55. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB (2008) Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol 75: 405–413. 56. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280: 34202–34209. 57. Kou R, Sartoretto J, Michel T (2009) Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta. J Biol Chem 284: 14734–14743. 58. Allal C, Favre G, Couderc B, Salicio S, Sixou S, et al. (2000) RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275: 31001–31008. 59. Menna PL, Parera RL, Cardama GA, Alonso DF, Gomez DE, et al. (2009) Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing beta2-chimaerin. Mol Med Report 2: 97–102. 60. Ridley AJ (2001) Rho GTPases and cell migration. J Cell Sci 114: 2713–2722. 61. Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322–334. 62. Weiss S, Frischknecht K, Greutert H, Payeli S, Steffel J, et al. (2007) Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway. J Vasc Res 44: 149–156. 63. Kiyan J, Kusch A, Tkachuk S, Kramer J, Haller H, et al. (2007) Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis 195: 254–261. PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38935